deltatrials
Completed PHASE2 NCT00053378

A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects

A Placebo-Controlled, Double-Blind Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects

Sponsor: Abbott

Conditions Hypocalcemia
Interventions Administration of elemental Ca during hypocalcemic ICU pts. Effects on calcium regulation paricalcitol injection (Zemplar)
Updated 5 times since 2017 Last updated: Jul 31, 2006 Started: Jan 31, 2002

Listed as NCT00053378, this PHASE2 trial focuses on Hypocalcemia and remains completed. Sponsored by Abbott, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abbott
Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethlehem, United States
  • • Chicago, United States
  • • Denver, United States
  • • Hopewell, United States
  • • Hudson, United States
  • • Lexington, United States
  • • Merced, United States
  • • Orlando, United States
  • • Rochester, United States